Print Page | Close Window


January 20, 2017 - 5:49 a.m.
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Printer Friendly Version 
January 11, 2017 - 6:53 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Printer Friendly Version 
January 10, 2017 - 9:01 a.m.
Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Printer Friendly Version 
January 03, 2017 - 4:31 p.m.
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Printer Friendly Version